

CRIS-Princess Margaret Cancer Centre Drug Development Fellowship Program

ABOUT THE FELLOWSHIP

The BRAS Drug Development Fellowship Program is a world class training program in experimental therapeutics with a mentorship track record of over 50 trainees in the last two decades. The Fellowship, directed by Dr. Anna Spreafico, is part of the Drug Development Program at the Princess Margaret Cancer Centre, University Health Network (PM-UHN) and includes 4 to 8 clinical research fellows annually. This year, CRIS and the Phase I Clinical Trials Program PM-UHN are co-funding one fellowship candidate.

Purpose

The goal of the CRIS-PM Drug Development Fellowship is to train early career investigators from Spain, France and UK (and potentially other countries) at the PM-UHN in Toronto, Canada, in experimental therapeutics and translational research. Applicants to the CRIS-PM Drug Development Fellowship are expected to complete a two-years training in the Phase I Clinical Trials Program, following their board certification in Medical Oncology in Spain or another acceptable jurisdiction.

Eligibility

Applicants must meet the following criteria:

- Board Certified Medical Oncologist or MD who completed the Internal Medicine Residency Program and is board eligible
- Spain, France or UK nationality (other countries may be considered)
- English proficiency in reading and writing

FELLOWSHIP PROGRAM TERMS AND CONDITIONS

The fellowship has a structured curriculum that includes active participation in the planning, coordination and implementation of selected clinical trial protocols conducted by the PM-UHN Phase I Clinical Trials Program. Fellows develop skills in writing protocols and letters of intent; analyzing clinical trial and correlative sciences data; presenting results at local, national and international meetings; and preparing peer-reviewed manuscripts for publication. Fellows are assigned to a clinical trial patient roster for about one day per week, during which time they will assess patients actively participating in trials run by the Phase I Clinical Trials Program with staff guidance and supervision. This provides broad hands-on experience with the day-to-day conduct of early phase clinical trials, including patient assessment, toxicity management and attribution, record keeping, and communication with the study team and trial sponsors. In addition, fellows



participate in 3 half-day ambulatory medical oncology clinics per week to gain additional expertise in their disease sites of interest, which include the weekly phase I new referral assessment clinic. A minimum of fifty-percent of the fellows' time is protected for clinical research.

APPLICATION PROCESS

Each Candidate must provide the following:

- Curriculum Vitae (maximum 4 page)
- Motivation Statement (maximum 500 words)
 - Brief Summary of your training and academic interest
 - What drives you to pursue the CRIS-PM Drug Development Fellowship Program?
 - How would attending the CRIS-PM Drug Development Fellowship Program impact your career?

Selection Process and Funding

Applications will be processed as received on an ongoing basis. Incomplete application packages will not be considered. A committee will review of the full application package and the selected candidates will be interviewed virtually. The successful candidate will receive a formal acceptance letter. A maximum of two-year fellowship award will be supported. The annual funding consists in CAD \$95,000 (plus 11% benefits) for a gross salary of CAD \$105,450.

DATES

- Application Submission deadline: May 30th 2023
- Fellowship Start Date: July 1, 2023 (start date may be adjusted)
- Please submit your application to diana.Burgos@uhn.ca